Stay updated on Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision was updated to v3.6.3, replacing the previous v3.6.2. This indicates a minor update to the page’s documentation or formatting rather than changes to the study content.SummaryDifference0.1%

- Check18 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, indicating a small publication/backend update without changes to the study details.SummaryDifference0.1%

- Check32 days agoChange DetectedThe study page now indicates that enrollment is closed with a 'No longer looking for participants' note, and new help/navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study) while the Intervention/Treatment header formatting was adjusted and the revision version updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check39 days agoChange DetectedRevision label updated from v3.5.4 to v3.5.5. This reflects an update to the site's revision tracking rather than substantive changes to the study details.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page now displays a new revision tag: Revision: v3.5.4. The previous revision tag Revision: v3.5.3 has been removed.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a change in the site release rather than study details.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.